A Long-term, Multi-center, Longitudinal Post-marketing, Observational Study to Assess Long Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children With Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA) (STRIVE)

07/08/2019
24/03/2025
EU PAS number:
EUPAS30576
Study
Finalised

ENCePP Code of conduct

No
Data sources

Data sources (types)

Disease registry
Other

Data sources (types), other

Spontaneous reporting system, Prospective patient-based data collection
Use of a Common Data Model (CDM)

CDM mapping

No
Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes
Data characterisation

Data characterisation conducted

Unknown
Procedures
No information provided.